Back to today’s briefing

Story perspectives

Revolutionary Cancer Research Unveiled at ASCO 2025 Symposium

1/23/2025

39 3

Summary

Story summary

Natera, ALX Oncology, and Exact Sciences are set to unveil groundbreaking research at the 2025 ASCO Gastrointestinal Cancers Symposium in San Francisco from January 23-25. Natera will reveal promising data on Signatera™ for colorectal cancer, ALX will highlight evorpacept's success in HER2-positive gastric cancer, and Exact Sciences will showcase its innovative Oncodetect™ MRD test, marking a leap forward in cancer detection.

History

Historical Context

Natera, ALX Oncology, and Exact Sciences' upcoming presentations at the 2025 ASCO Gastrointestinal Cancers Symposium reflect a growing trend in cancer research. Historically, breakthroughs in cancer detection and treatment have accelerated since the 1990s, driven by advances in genomics and immunotherapy. This symposium continues the legacy of collaborative efforts to improve cancer outcomes, echoing past milestones in oncological research.

1 of 2

Story summary

Natera, ALX Oncology, and Exact Sciences are set to unveil groundbreaking research at the 2025 ASCO Gastrointestinal Cancers Symposium in San Francisco from January 23-25. Natera will reveal promising data on Signatera™ for colorectal cancer, ALX will highlight evorpacept's success in HER2-positive gastric cancer, and Exact Sciences will showcase its innovative Oncodetect™ MRD test, marking a leap forward in cancer detection.

1 / 2